238 related articles for article (PubMed ID: 27824928)
1. Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
Teshima T; Matsumoto H; Okusa T; Uchiyama R; Koyama H
PLoS One; 2016; 11(11):e0166267. PubMed ID: 27824928
[TBL] [Abstract][Full Text] [Related]
2. Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.
Teshima T; Matsumoto H; Okusa T; Nakamura Y; Koyama H
PLoS One; 2015; 10(8):e0135516. PubMed ID: 26262685
[TBL] [Abstract][Full Text] [Related]
3. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
4. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE
Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Vet Rec; 2008 Oct; 163(16):477-81. PubMed ID: 18931355
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
Woolcock AD; Bugbee AC; Creevy KE
J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
[TBL] [Abstract][Full Text] [Related]
7. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
8. Plasma profiles of adrenocorticotropic hormone, cortisol, alpha-melanocyte-stimulating hormone, and growth hormone in dogs with pituitary-dependent hyperadrenocorticism before and after hypophysectomy.
Hanson JM; Kooistra HS; Mol JA; Teske E; Meij BP
J Endocrinol; 2006 Sep; 190(3):601-9. PubMed ID: 17003261
[TBL] [Abstract][Full Text] [Related]
9. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
11. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
13. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.
Bell R; Neiger R; McGrotty Y; Ramsey IK
Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism.
Bosje JT; Rijnberk A; Mol JA; Voorhout G; Kooistra HS
Domest Anim Endocrinol; 2002 Jun; 22(4):201-10. PubMed ID: 12044610
[TBL] [Abstract][Full Text] [Related]
15. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Arenas Bermejo C; Pérez Alenza D; García San José P; Llauet L; Pérez-López L; Melián C; C Feldman E
J Vet Intern Med; 2020 Jul; 34(4):1413-1422. PubMed ID: 32533623
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness to corticotropin-releasing hormone and vasopressin in canine Cushing's syndrome.
van Wijk PA; Rijnberk A; Croughs RJ; Wolfswinkel J; Selman PJ; Mol JA
Eur J Endocrinol; 1994 Apr; 130(4):410-6. PubMed ID: 8162173
[TBL] [Abstract][Full Text] [Related]
17. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis.
Teshima T; Hara Y; Takekoshi S; Nezu Y; Harada Y; Yogo T; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):32-44. PubMed ID: 19041802
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism.
Braun C; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2013 Oct; 155(10):551-8. PubMed ID: 24091230
[TBL] [Abstract][Full Text] [Related]
19. The effect of 1 year of trilostane treatment on peripheral lymphocyte subsets in dogs with pituitary-dependent hyperadrenocorticism.
Oda H; Mori A; Shono S; Onozawa E; Sako T
J Vet Med Sci; 2016 Jun; 78(5):851-4. PubMed ID: 26782012
[TBL] [Abstract][Full Text] [Related]
20. Corticotropin-releasing hormone and adrenocorticotropic hormone concentrations in cerebrospinal fluid of dogs with pituitary-dependent hyperadrenocorticism.
Van Wijk PA; Rijnberk A; Croughs RJ; Voorhout G; Sprang EP; Mol JA
Endocrinology; 1992 Dec; 131(6):2659-62. PubMed ID: 1332844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
